First Hawaiian Bank Decreases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

First Hawaiian Bank trimmed its position in ADMA Biologics, Inc. (NASDAQ:ADMAGet Rating) by 26.8% during the 1st quarter, Holdings Channel reports. The institutional investor owned 375,781 shares of the biotechnology company’s stock after selling 137,810 shares during the period. First Hawaiian Bank’s holdings in ADMA Biologics were worth $688,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ADMA. ProShare Advisors LLC purchased a new position in shares of ADMA Biologics in the fourth quarter worth $39,000. Credit Suisse AG purchased a new position in shares of ADMA Biologics in the third quarter worth $40,000. Exane Derivatives purchased a new position in shares of ADMA Biologics in the fourth quarter worth $40,000. Shay Capital LLC purchased a new position in shares of ADMA Biologics in the fourth quarter worth $41,000. Finally, Lazard Asset Management LLC purchased a new position in shares of ADMA Biologics in the fourth quarter worth $55,000. 55.15% of the stock is currently owned by institutional investors.

Separately, StockNews.com initiated coverage on shares of ADMA Biologics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $5.70.

Shares of ADMA Biologics stock opened at $2.15 on Thursday. The company has a current ratio of 7.60, a quick ratio of 3.19 and a debt-to-equity ratio of 1.15. The company’s fifty day simple moving average is $1.95 and its two-hundred day simple moving average is $1.69. The company has a market cap of $421.23 million, a P/E ratio of -4.32 and a beta of 1.07. ADMA Biologics, Inc. has a 12-month low of $1.01 and a 12-month high of $2.32.

ADMA Biologics (NASDAQ:ADMAGet Rating) last issued its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $29.10 million for the quarter, compared to analysts’ expectations of $26.50 million. ADMA Biologics had a negative net margin of 83.27% and a negative return on equity of 59.36%. During the same period in the previous year, the firm posted ($0.16) earnings per share. Analysts predict that ADMA Biologics, Inc. will post -0.29 EPS for the current fiscal year.

ADMA Biologics Profile (Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Further Reading

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMAGet Rating).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.